Abstract 867: Incidence of molecular alterations in KRAS and other known cancer genes in patients with pancreatic cancer assessed with a commercial genomic profiling panel compared to TCGA results

Background: The Cancer Genome Atlas (TCGA) characterizes somatic mutations of pancreatic cancer (PC) patients (pts) using whole-exome sequencing (WES, mean coverage 405x) of fresh frozen tumor tissues and matched blood samples. In addition, it includes a confirmation of the key genomic findings by a targeted sequencing panel (~644x) and microfluidic PCR-based sequencing (~30,000x). For the vast majority of patients who do not undergo resection,...